Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
but activates HIF stabilization and nuclear translocation
MLN8237 is currently in Phase II study for treatment of patients with ovarian
ATB-346 exerts superior chemopreventive effects to those of naproxen
ent-crizotinib
AG-221 (Enasidenib) - IHD2 Inhibitor. CAS# 1446502-11-9 size:Contact [email protected] for quotation shows reduction of atherosclerosis inEnasidenib, also known as AG 221 and CC 90007, CAS No. 1446502 11 9, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2). The mutations of IDH2 present in certain cancer cells result in a new ability of the enzyme to catalyze the NAPH dependent reduction of ketoglutarate to R( ) 2 hydroxyglutarate (2HG). The production of 2HG is believed to contribute to the formation and progression of
US$ 325.00
US$ 2750.00
US$ 150.00
US$ 120.00
US$ 350.00
US$ 150.00
US$ 1075.00